Financials data is unavailable for this security.
View more
Year on year Medistim ASA had net income fall -8.90% from 113.97m to 103.82m despite a 7.00% increase in revenues from 491.94m to 526.36m. An increase in the selling, general and administrative costs as a percentage of sales from 31.31% to 32.37% was a component in the falling net income despite rising revenues.
Gross margin | 79.12% |
---|---|
Net profit margin | 18.58% |
Operating margin | 23.30% |
Return on assets | 21.05% |
---|---|
Return on equity | 25.95% |
Return on investment | 25.53% |
More ▼
Cash flow in NOKView more
In 2023, Medistim ASA did not generate a significant amount of cash. However, the company earned 113.19m from its operations for a Cash Flow Margin of 21.50%. In addition the company used 29.73m on investing activities and also paid 84.88m in financing cash flows.
Cash flow per share | 6.91 |
---|---|
Price/Cash flow per share | 19.98 |
Book value per share | 22.12 |
---|---|
Tangible book value per share | 19.13 |
More ▼
Balance sheet in NOKView more
Current ratio | 4.82 |
---|---|
Quick ratio | 2.75 |
Total debt/total equity | 0.0185 |
---|---|
Total debt/total capital | 0.0181 |
More ▼
Growth rates in NOK
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -9.00%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked the highest relative to its industry peers.
Div yield(5 year avg) | 1.47% |
---|---|
Div growth rate (5 year) | 14.87% |
Payout ratio (TTM) | 80.78% |
EPS growth(5 years) | 12.58 |
---|---|
EPS (TTM) vs TTM 1 year ago | -13.41 |
More ▼